Investment Rating - The report maintains an "Overweight" rating for the following A-share companies: Heng Rui Medicine, Yifang Bio, WuXi AppTec, Kailai Ying, Tigermed, United Imaging, Microelectrophysiology, Tongce Medical, Aier Eye Hospital, and Haizhi Science. These companies are included in the Guotai Junan Medical March 2026 portfolio [8][9] - The report also maintains an "Overweight" rating for the following H-share companies: Hansoh Pharmaceutical, 3SBio, CSPC Pharmaceutical Group, BeiGene, Kelun-Biotech, Innovent Biologics, CanSino Biologics, Precision Medicine, United Pharmaceutical, and Rongchang Biologics [8][10] Core Insights - The report continues to recommend the innovative pharmaceutical and medical device industry chain [2] - In February 2026, the pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index rising by 1.1% while the SW Pharmaceutical and Biological Index fell by 0.2%, ranking 23rd among Shenwan's first-level industries [12][21] - The report highlights that the pharmaceutical sector's premium level relative to all A-shares is currently at a normal level, with a relative premium rate of 67.0% as of the end of February 2026 [18][21] Summary by Sections 1. Continued Recommendation for Innovative Pharmaceutical and Medical Device Industry Chain - The report emphasizes the ongoing recommendation for the innovative pharmaceutical and medical device industry chain [2] 2. February 2026 Pharmaceutical Sector Performance - The pharmaceutical sector underperformed the market in February 2026, with a decline of 0.2% compared to a 1.1% increase in the Shanghai Composite Index [12][21] - Among the sub-sectors, Traditional Chinese Medicine (+1.5%), Chemical Raw Materials (+1.3%), and Medical Devices (+0.9%) performed relatively well [14] 3. Performance of Hong Kong and US Pharmaceutical Sectors - In February 2026, the Hong Kong pharmaceutical sector outperformed the broader market, with the Hang Seng Medical Care Index declining by 2.1% and the Hang Seng Biotechnology Index by 1.2%, while the Hang Seng Index fell by 2.8% [21] - The US pharmaceutical sector also showed strength, with the S&P Healthcare Select Sector Index increasing by 3.6%, compared to a 0.9% decline in the S&P 500 [21]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for overseas listing applications for 11 companies, focusing on compliance, ownership structure, and business operations [1][2][3]. Group 1: Supplementary Material Requirements - For Avita, the requirements include clarifying the legality and fairness of past capital increases and share transfers, particularly regarding transactions at nominal or zero consideration, and the existence of shareholding proxies [1][14]. - For TuoSiDa, the focus is on the specific use of raised funds, the proportion of domestic versus overseas use, and whether necessary approvals for overseas investments have been obtained [2][5]. - For TianXiaXiu, the company must provide detailed operational information regarding its advertising and consulting services, along with legal opinions from lawyers [2][6]. - For JunSai Bio, the requirements include clarifying the actual controller's permanent residency status abroad and any historical shareholding proxies [2][9]. Group 2: Compliance and Legal Opinions - Companies are required to provide legal opinions confirming the compliance of their business operations with foreign investment regulations, particularly concerning sensitive sectors like stem cells and gene therapy [7][16]. - The CSRC emphasizes the need for companies to disclose any potential legal issues related to share pledges or freezes that may affect the listing process [10][18]. - Companies must also clarify their operational activities related to data protection and user information management, especially in the context of digital products and services [14][8]. Group 3: Ownership and Control Structure - Companies must explain discrepancies between their current and post-listing controlling shareholder structures, particularly in relation to the disclosures made in their prospectuses [2][14]. - The requirements include a thorough examination of the historical decisions made by the board and shareholder meetings to ascertain control rights [2][14]. - Companies are also asked to confirm whether their major shareholders are subject to any legal restrictions on ownership [13][17]. Group 4: Financial and Operational Transparency - Companies must detail the pricing basis for any recent share transfers and whether there are any irregularities or potential conflicts of interest [9][17]. - The CSRC requires companies to disclose their fundraising plans, including the expected amount and the implications of exercising any over-allotment options [12][18]. - Companies are also asked to provide insights into their business models, including customer and supplier relationships, and how these align with their market positioning [18].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [1] Core Insights - The upcoming adjustment of the National Essential Medicines List (NEML) is expected to benefit traditional Chinese medicine (TCM) stocks, with a focus on companies like Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17][22] - The report ranks sub-sectors in the following order of preference: innovative drugs > research services > CXO > TCM > medical devices > pharmacies [2][11] - Historical data indicates that products included in the NEML tend to experience significant sales growth, as seen with Zhaoli Pharmaceutical's Wuling Capsule, which saw sales growth rates increase from -12.82% in 2017 to 32.52% in 2021 after being included in the NEML [19][22] Summary by Sections Investment Highlights - The report suggests focusing on TCM stocks due to the imminent NEML adjustments, recommending Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17] - The report emphasizes the importance of the NEML adjustments, which have not occurred in eight years, and the potential for TCM products to gain market share [22] R&D Progress and Company Dynamics - Recent approvals and submissions include Sanofi's Dupilumab for new indications and GSK's hepatitis B therapy application in Japan [5] - The report highlights various companies across different therapeutic areas, including innovative drugs, ADCs, and small nucleic acids, suggesting a diversified investment approach [13][22] Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 3.0%, with notable performances from specific stocks such as Aidi Te (+36.9%) and Wanze Shares (+27.5%) [10] - The report notes that the medical sector has seen varied performance, with biopharmaceuticals and medical devices showing positive trends, while chemical pharmaceuticals and medical services have faced declines [10]

Core Viewpoint - The company Yifang Biotechnology (Shanghai) Co., Ltd. held its first extraordinary general meeting of shareholders in 2026 to approve adjustments to the internal investment structure of certain fundraising projects, with a high approval rate of 99.7263% [1] Group 1: Meeting Details - The extraordinary general meeting was convened on February 26, 2026, and followed legal procedures as confirmed by Junhe Law Firm [1] - A total of 218,902,289 shares were represented at the meeting, accounting for 37.8495% of the company's total share capital [1] - The voting method combined on-site and online participation, with 175,755,934 shares represented in person and 43,146,355 shares via online voting [1] Group 2: Voting Results - The proposal to adjust the internal investment structure was passed with a 99.7263% approval rate, while dissenting votes accounted for 0.2689% and abstentions for 0.0048% [1] - The company conducted a separate vote counting for small and medium investors [1] Group 3: Agenda Changes - Originally, multiple proposals were to be reviewed at the meeting, but the board of directors announced the cancellation of some proposals on February 14, 2026 [1] - Relevant meeting materials were disclosed as required prior to the meeting [1]

Core Viewpoint - The company held its first extraordinary general meeting of shareholders in 2026, where all proposed resolutions were approved without any rejections [2][4]. Group 1: Meeting Details - The meeting was convened on February 26, 2026, at a location in Shanghai [5]. - The meeting was chaired by Mr. Yaolin Wang and utilized a combination of on-site and online voting methods, complying with the Company Law and the company's articles of association [2][4]. Group 2: Attendance and Legal Verification - All nine current directors and the company secretary attended the meeting, along with other senior management [3]. - The meeting was witnessed by lawyers from JunHe Law Offices, who confirmed that the procedures followed were in accordance with relevant laws and regulations, and the resolutions made were valid [6]. Group 3: Financial Performance Overview - For the fiscal year 2025, the company expects to achieve a revenue of 37.3253 million yuan, with a net loss attributable to shareholders of approximately 316.8384 million yuan [8][13]. - The decline in revenue is attributed to variations in income from technology licensing and cooperation, which differ from year to year [13]. Group 4: Operational Insights - The company's performance in 2025 was significantly influenced by its high level of research and development (R&D) investment, with several core clinical projects reaching critical stages [11]. - The company is advancing multiple clinical trials, including a Phase III trial for D-0502 and various trials for D-2570 and D-0120, indicating a robust pipeline [11][12]. Group 5: Financial Data Summary - The company anticipates a gross profit of approximately -316.5959 million yuan and a total profit of -316.5989 million yuan for 2025, reflecting an increase in losses compared to the previous year [13]. - The expected net loss after excluding non-recurring items is projected to be around -328.8111 million yuan [13].

Group 1 - The core point of the article is that Yifang Bio reported a significant decline in its financial performance for the year 2025, with total operating revenue of 37.3253 million yuan, representing a year-on-year decrease of 77.89% [2] - The net profit attributable to the parent company was reported at -316.8384 million yuan, indicating a substantial loss for the company [2]

Group 1 - The company reported a revenue of 37.3253 million yuan for the fiscal year 2025, representing a year-on-year decline of 77.89% [1] - The net profit attributable to shareholders was a loss of 317 million yuan, compared to a loss of 240 million yuan in the same period last year [1] - The basic earnings per share were -0.55 yuan [1]

君合律师事务所上海分所（以下简称"本所"）接受益方生物科技（上海） 股份有限公司（以下简称"公司"）的委托，指派本所律师列席了公司于 2026 年 2 月 26 日在上海市浦东新区张衡路 1000 弄 63 号召开的 2026 年第一次临时股 东会（以下简称"本次股东会"）的现场会议。现本所根据《中华人民共和国公 司法》（以下简称"《公司法》"）《中华人民共和国证券法》《上市公司股东 会规则》（以下简称"《股东会规则》"）等中国现行法律、法规和规范性文件 以及《益方生物科技（上海）股份有限公司章程》（以下简称"《公司章程》"） 《益方生物科技（上海）股份有限公司股东会议事规则》的有关规定，就本次股 东会有关事宜出具法律意见书。 上海石门一路 288 号 兴业太古汇香港兴业中心一座 26 层 邮编：200041 电话：（86-21）5298 5488 传真：（86-21）5298 5492 junhesh@junhe.com 君合律师事务所上海分所 关于益方生物科技（上海）股份有限公司 2026 年第一次临时股东会的法律意见书 致：益方生物科技（上海）股份有限公司 本法律意见书仅就本次股东会的召集和召开程序是否 ...

证券代码：688382 证券简称：益方生物 公告编号：2026-010 （二） 股东会召开的地点：上海市浦东新区张衡路 1000 弄 63 号 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 益方生物科技（上海）股份有限公司 2026年第一次临时股东会决议公告 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 2 月 26 日 审议结果：通过 表决情况： | 1、出席会议的股东和代理人人数 | 221 | | --- | --- | | 普通股股东人数 | 221 | | 2、出席会议的股东所持有的表决权数量 | 218,902,289 | | 普通股股东所持有表决权数量 | 218,902,289 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 37.8495 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） ...

Financial Performance - Total revenue for 2025 is expected to be CNY 37.33 million, a decrease of 77.89% compared to the previous year[3] - The net profit attributable to shareholders of the parent company is projected to be CNY -316.84 million, worsening from CNY -240.20 million in the previous year[3] - The basic earnings per share for 2025 is projected at CNY -0.55, compared to CNY -0.42 in the previous year[3] - The company’s weighted average return on net assets is projected to be -18.91%[3] - The company expects to continue incurring losses in 2025 due to high R&D costs and insufficient revenue from technology licensing and cooperation[7] Assets and Equity - The total assets decreased by 11.29% to CNY 1,703.88 million from CNY 1,920.82 million at the beginning of the period[4] - The equity attributable to shareholders of the parent company fell by 15.17% to CNY 1,536.14 million[4] Research and Development - The company maintained a high level of R&D investment, with ongoing clinical trials for multiple core projects, including D-0502 and D-2570[5] - The company is advancing two innovative preclinical candidates, YF087 and YF550, which show promising anti-tumor potential[6] - The company emphasizes the importance of ongoing R&D and technology platform development for long-term growth[6]